Physician profile
John P Everett
NPI 1336195759
$7,276.77
in general payments reported to CMS, 2019-2025
21 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $434 · 2021: $153 · 2022: $662 · 2023: $994 · 2024: $3,589 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,930 · Travel and Lodging: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,929.79 |
| Travel and Lodging | $1,375.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,262.25 | 2020-2025 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $2,122.00 | 2019-2025 | |
| Pfizer INC. | $558.23 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $541.64 | 2019-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $324.62 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $263.72 | 2023-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.73 | 2023-2025 | Jardiance |
| Amgen INC. | $203.99 | 2019-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $139.32 | 2024-2025 | Camzyos |
| Bridgebio Pharma, INC. | $129.25 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $111.79 | 2022-2025 | |
| Boston Scientific Corporation | $81.63 | 2023-2025 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $75.85 | 2024-2025 | Onpattro, Amvuttra |
| Philips North America LLC | $51.02 | 2025 | Dose Professional Services, Mcot |
| Kiniksa Pharmaceuticals International, Plc | $40.42 | 2024 | Arcalyst |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $28.18 | 2024 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $24.46 | 2024 | |
| Novo Nordisk INC | $20.71 | 2025 | Ozempic |
| Baxter Healthcare | $17.14 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Actelion Pharmaceuticals US, INC. | $16.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Everett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.